Clinical trials: Endocrine, Metabolic or Nutritional Diseases or Conditions
Obesity, Diabetes Mellitus, Type 2
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or…
- Trial name
- SYNCHRONIZE™-2 (NCT06066528)
- Testing
- Survodutide
- Where
- 143 sites in United States, Australia and 17 more
- Volunteers
- 755 people
- Sponsor
- Boehringer Ingelheim
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Therapeutic Education Program, Emergencies
Predictors of Non-accESs to therapeutiC EducAtion Programs Among Patients With Type 2 Diabetes, and/or Asthma, and/or Chronic Heart Failure in an Emergency Setting
Chronic diseases are frequent and potentially severe. Type II diabetes, asthma and heart failure affect 3.3 million, 4 million and 1 million people respectively in France.
- Conditions
- Therapeutic Education Program, Emergencies, Diabetes, Asthma
- Trial name
- ESCAPE (NCT05320276)
- Where
- France
- Volunteers
- 297 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Diabetes Mellitus, Type 2
Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35
The aim of this study is to evaluate the effect of Roux-en-y gastric bypass (RYGB) in controlling diabetes in subjects with mild obesity (BMI 26-35).
- Trial name
- NCT00999050
- Testing
- Gastric bypass for diabetic patients <35 BMI
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Polycystic Ovary Syndrome, Obesity
Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries.
- Trial name
- OMgObPCOS (NCT02521753)
- Testing
- Metformin, Magnesium, PUFA
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Diabetes, Gestational, Insulin Resistance
Metformin in Gestational Diabetes Mellitus
Gestational diabetes (GDM) is a condition that manifests as high blood sugar levels (hyperglycemia) during pregnancy in previously healthy women.
- Trial name
- MetGDM (NCT00681460)
- Testing
- human recombined insulin, metformin
- Where
- Poland
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- K. Marcinkowski University of Medical Sciences
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01704079
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- OPKO IP Holdings II, Inc.
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a…
- Trial name
- NCT06297603
- Testing
- Retatrutide
- Where
- 76 sites in United States, Argentina and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Coronary Disease
A Study Comparing Standard Care for Diabetes to Case-managed Care for Diabetes in Patients With Coronary Artery Disease
The purpose of this study is to compare two ways to treat patients with Type 2 Diabetes, Standard Care or Case-Managed Care. In-Patient Standard Care is guided by the assigned cardiologist and Out-Patient Standard Care by the…
- Trial name
- NCT00248352
- Testing
- Consultation with Endocrinologist, Counseling from Dietician, Counseling from Diabetes Educator
- Where
- Canada
- Volunteers
- 169 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Depression, Diabetes
Effectiveness of a mHealth Intervention for the Treatment of Depression in People With Diabetes or Hypertension in Peru
Background: Depression is a common comorbidity of physical chronic diseases such as diabetes and/or hypertension and constitutes an important public health problem.
- Conditions
- Depression, Diabetes, Hypertension
- Trial name
- LATIN-MHPeru (NCT03026426)
- Testing
- CONEMO
- Where
- 8 sites in Peru
- Volunteers
- 432 people
- Sponsor
- Universidad Peruana Cayetano Heredia
Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment
Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection
Diabetes is a major factor of morbi-mortality in Covid-19 infection. Currently, steroid therapy is required in patients under oxygen therapy. This treatment is associated with hyper glycaemia in patients with diabetes.
- Trial name
- COVIDEX (NCT04726163)
- Testing
- Continuous blind glucose measurement device (Free style Pro)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Strasbourg, France
Diabetes Mellitus, Type 2, Cardiovascular Diseases
The Cardio-Metabolic Clinic
This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease.
- Trial name
- ProtecT-2-D (NCT06203860)
- Testing
- Cardio-Metabolic Clinic
- Where
- Denmark
- Volunteers
- 1,600 people
- Sponsor
- Odense University Hospital
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease
This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney…
- Trial name
- NCT01363336
- Testing
- Nifedipine (Adalat CR, BAYA1040)
- Where
- Japan
- Volunteers
- 1,882 people
- Sponsor
- Bayer
Infections Joint Prosthetic, Overweight or Obesity
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
To determine the effectiveness of a 7-day course of an oral, prophylactic antibiotic on the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk…
- Conditions
- Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA
- Trial name
- NCT04297592
- Testing
- Cephalexin, Doxycycline, Cefadroxil
- Where
- 2 sites in United States
- Volunteers
- 4,618 people
- Sponsor
- Mayo Clinic
Sleep Apnea, PreDiabetes
Technology-Supported Treatment of Sleep Apnea in Prediabetes
Despite the efficacy of intensive lifestyle interventions in prediabetes, the incidence of diabetes is rising, and thus there is a critical need for additional strategies to prevent diabetes and to reduce its cardiovascular…
- Conditions
- Sleep Apnea, PreDiabetes, Overweight or Obesity
- Trial name
- TECH (NCT04225507)
- Testing
- Diet and exercise coaching, CPAP Treatment
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- University of Chicago
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel